Substance-induced or substance-associated primary psychoses? Continuing the discussion. A response to I.А. Fedotov, et al

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


This letter to the editor continues the discussion about the similarities and differences between secondary psychosis and schizophrenia, which was initiated by the authors of the article «Substance-induced psychosis and schizophrenia: the interaction point» (Fedotov I.A., Quattrone D., Shustov D.I. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. doi:10.238 88/PAVLOVJ2020284593-604).


Full Text

Restricted Access

About the authors

Michelle Cherro

American University of Beirut

Author for correspondence.
Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-4526-2595

Lebanon, Beirut, Lebanon

MD, Post-Graduate Resident, Department of Psychiatry, Faculty of Medicine

Chonnakarn Jatchavala

Prince of Songkla University

Email: mc119@aub.edu.lb
ORCID iD: 0000-0001-9765-2184

Thailand, Songkla, Hat Yai, Thailand

MD, M.Sc., Department of Psychiatry, Faculty of Medicine

DJibril I.M. Handuleh

Saint Paul's Hospital Millennium Medical College

Email: mc119@aub.edu.lb
ORCID iD: 0000-0003-2662-1078

Ethiopia, Addis Ababa, Ethiopia

MD, Resident, Department of Psychiatry

Ramdas Ransing

BKL Walawalkar Rural Medical College

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-5040-5570

India, Maharashtra, India

MD, Assistant Professor, Department of Psychiatry

Sheikh Shoib

Jawahar Lal Nehru Memorial Hospital

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-3739-706X

India, Rainawari, Kashmir, India

MD, Psychiatrist, Department of Psychiatry

Dorottya Őri

Heim Pál National Pediatric Institute

Email: mc119@aub.edu.lb
ORCID iD: 0000-0003-0878-165X

Hungary, Budapest, Hungary

MD, Child and adolescent psychiatrist, Department of Mental Health

Margaret Isioma Ojeahere

Jos University Teaching Hospital

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-0593-2400

Nigeria, Jos, Plateau State, Nigeria

MD, Psychiatrists, Department of Psychiatry

Joan Soler-Vidal

FIDMAG Research Foundation

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-9809-8477

Spain, Barcelona, Spain

MD, Researcher

Victor Pereira-Sanchez

NYU Grossman School of Medicine

Email: mc119@aub.edu.lb
ORCID iD: 0000-0002-2576-1549

United States, New York, USA

MD, Clinical Instructor

References

  1. Beckmann D, Lowman KL, Nargiso J, et al. Substance-induced Psychosis in Youth. Child and Adolescent Psychiatric Clinics of North America. 2020; 29(1):131-43. doi: 10.1016/j.chc.2019.08.006
  2. Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-induced psychoses: a critical review of the literature. Current Drug Abuse Reviews. 2011;4(4): 228-40. doi: 10.2174/1874473711104040228
  3. Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of Psychotic Symptoms in Substance Users: A Comparison across Substances. Comprehensive Psychiatry. 2009;50(3):245-50. doi: 10.1016/j.comp psych.2008.07.009
  4. Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectrums. 2016; 21(4):349-54. doi: 10.1017/S1092852916000316
  5. Kraan T, Velthorst E, Koenders L, et al. Cannabis use and transition to psychosis in individuals at ultra-high risk: review and metaanalysis. Psychological Medicine. 2016;46(4):673-81. doi: 10.1017/S00332 91715002329
  6. Fedotov IA, Quattrone D, Shustov DI. Substance-induced psychosis and schizophrenia: the interaction point. I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):593-604. (In Russ). doi:10.23888/ PAVLOVJ2020284593-604
  7. Ham S, Kim TK, Chung S, et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology. 2017;26(1):11-24. doi: 10.5607/en.2017.26.1.11
  8. Dragogna F, Mauri MC, Marotta G, et al. Brain Metabolism in Substance-Induced Psychosis and Schizophrenia: A Preliminary PET Study. Neuropsychobiology. 2014;70(4):195-202. doi:10.1159/ 000366485
  9. Fischer M. Psychoses in the offspring of schizophrenic monozygotic twins and their normal cotwins. The British Journal of Psychiatry. 1971;118 (542):43-52. doi: 10.1192/bjp.118.542.43
  10. Ziedonis DM, Fisher W. Assessment and Treatment of Comorbid Substance Abuse in Individuals with Schizophrenia. Psychiatric Annals. 1994;24(9):477-83. doi: 10.3928/0048-5713-19940901-10
  11. Jatchavala C, Vittayanont A. Post-Traumatic Stress Disorder Symptoms among Patients with Substance-Related Disorders in the Restive A. Songklanagarind Medical Journal. 2017;35(2):121-32. doi: 10.31584/smj.2017.35.2.694
  12. Fowles DC. Schizophrenia: diathesis-stress revisited. Annual Review of Psychology. 1992;43:303-36. doi: 10.1146/annurev.ps.43.020192.001511
  13. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin. 1990;16(1):31-56. doi: 10.1093/schbul/16.1.31
  14. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review Psychiatry. 1999; 6(6):287-96. doi: 10.3109/10673229909017206
  15. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors. 1998;23(6):717-34.
  16. Khokhar JY, Dwiel LL, Henricks AM, et al. The link between schizophrenia and substance use disorder: a unifying hypothesis. Schizophrenia Research. 2018;194:78-85. doi: 10.1016/j.schres.2017.04.016
  17. Guloksuz S, van Os J. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine. 2018; 48(2):229-44. doi: 10.1017/S0033291717001775
  18. Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. American Journal of Psychiatry. 2019;176(9):711-9. doi: 10.1176/appi. ajp.2019.18101217
  19. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. American Journal of Psychiatry. 2018;175(4):343-50. doi: 10.1176/appi.ajp.2017.17020223
  20. Deng X, Huang Z, Li X, et al. Long-term follow-up of patients treated for psychotic symptoms that persist after stopping illicit drug use. Shanghai Archives of Psychiatry. 2012;24(5):271-8. doi: 10.3969/j.issn. 1002-0829.2012.05.004
  21. Solanki RK, Singh P, Midha A, et al. Schizophrenia: Impact on quality of life. Indian Journal of Psychiatry. 2008;50(3):181-6. doi: 10.4103/0019-5545.43632
  22. Auquier P, Lançon C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiology and Drug Safety. 2006;15(12):873-9. doi: 10.1002/pds.1325
  23. McEvoy JP. The importance of early treatment of schizophrenia. Behavioral Healthcare. 2007;27(4):40-3

Statistics

Views

Abstract - 0

PDF (Russian) - 0

PDF (English) - 0

PDF (简体中文) - 0

Article Metrics

Metrics Loading ...

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2021 ООО "Эко-Вектор"



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies